GSK’s (GSK) “Buy” Rating Reaffirmed at Shore Capital

Shore Capital reissued their buy rating on shares of GSK (LON:GSK) in a research report report published on Wednesday, MarketBeat Ratings reports. The firm currently has a GBX 2,300 price target on the stock.

Other research analysts have also recently issued reports about the company. UBS Group reaffirmed a “neutral” rating and set a GBX 1,940 price objective on shares of GSK in a research note on Friday, January 23rd. Deutsche Bank Aktiengesellschaft raised their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research report on Thursday, January 15th. Berenberg Bank increased their price objective on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a report on Monday, November 24th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,100 target price on shares of GSK in a report on Wednesday, January 7th. Finally, Citigroup restated a “buy” rating and set a GBX 1,900 price objective on shares of GSK in a research note on Tuesday, January 27th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of GBX 1,867.86.

GSK Stock Performance

GSK traded up GBX 89.99 during trading on Wednesday, hitting GBX 2,035.49. 72,969,727 shares of the company traded hands, compared to its average volume of 10,179,397. The stock’s fifty day moving average is GBX 1,833.69 and its 200 day moving average is GBX 1,658.22. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. GSK has a one year low of GBX 1,242.50 and a one year high of GBX 2,066. The firm has a market cap of £82.13 billion, a P/E ratio of 15.30, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last issued its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

Insider Activity

In other GSK news, insider Wendy Becker purchased 441 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was purchased at an average cost of GBX 1,809 per share, with a total value of £7,977.69. Also, insider Jonathan Symonds bought 1,650 shares of GSK stock in a transaction dated Monday, December 22nd. The shares were bought at an average cost of GBX 1,810 per share, for a total transaction of £29,865. 0.20% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.